Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 28;118(4):1887-1916.
doi: 10.1021/acs.chemrev.7b00602. Epub 2018 Jan 31.

Hit Generation in TB Drug Discovery: From Genome to Granuloma

Tianao Yuan  1 , Nicole S Sampson  1   2
Affiliations
Review

Hit Generation in TB Drug Discovery: From Genome to Granuloma

Tianao Yuan et al. Chem Rev. .

Erratum in

Abstract

Current tuberculosis (TB) drug development efforts are not sufficient to end the global TB epidemic. Recent efforts have focused on the development of whole-cell screening assays because biochemical, target-based inhibitor screens during the last two decades have not delivered new TB drugs. Mycobacterium tuberculosis (Mtb), the causative agent of TB, encounters diverse microenvironments and can be found in a variety of metabolic states in the human host. Due to the complexity and heterogeneity of Mtb infection, no single model can fully recapitulate the in vivo conditions in which Mtb is found in TB patients, and there is no single "standard" screening condition to generate hit compounds for TB drug development. However, current screening assays have become more sophisticated as researchers attempt to mirror the complexity of TB disease in the laboratory. In this review, we describe efforts using surrogates and engineered strains of Mtb to focus screens on specific targets. We explain model culture systems ranging from carbon starvation to hypoxia, and combinations thereof, designed to represent the microenvironment which Mtb encounters in the human body. We outline ongoing efforts to model Mtb infection in the lung granuloma. We assess these different models, their ability to generate hit compounds, and needs for further TB drug development, to provide direction for future TB drug discovery.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing financial interest(s): T. Y. and N. S. S. are named inventors on patents and patent applications related to this article.

Figures

Figure 1
Figure 1
Diagrams of characteristic granulomas. (A) Cellular granuloma. Macrophages infected with Mtb (red) are at the center. Lipid bodies (white) are within foamy macrophages. (B) Necrotic granuloma. Macrophages have died and released Mtb into the necrotic center, which is hypoxic and filled with lipid caseum.
Figure 2
Figure 2
Chemical structures of front-line TB drugs.
Figure 3
Figure 3
Chemical structures of second-line TB drugs.
Figure 4
Figure 4
Hit compounds (A) identified in target-based whole-cell screens and (B) identified in whole-cell screen under growth culture conditions and discussed in the text. Also see Table 2.
Figure 5
Figure 5
Diagram of an Mtb-infected macrophage within the necrotic core of a granuloma illustrating the intracellular and extracellular microenvironments which Mtb encounters.
Figure 6
Figure 6
Hit compounds identified in whole-cell screens under stress culture conditions and discussed in the text. Also see Table 2.
Figure 7
Figure 7
Hit compound identified in intracellular whole-cell screens against Mtb-infected macrophages and discussed in the text. Also see Table 2.
Figure 8
Figure 8
TB compounds identified in the screens outlined in Table 2 that are currently in clinical trials.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO “Global Tuberculosis Report 2016”, World Health Organization, 2017 ; http://www.who.int/tb/publications/global_report/en/ accessed: 29 September 2017.
    1. CDC “Tuberculosis Fact Sheets”, Centers for Disease Control and Prevention, 2014 ; https://www.cdc.gov/tb/publications/factsheets/general/ltbiandactivetb.htm accessed: 22 December 2017.
    1. WHO “Collaborative Framework for Care and Control of Tuberculosis and Diabetes”, World Health Organization , 2017; http://www.who.int/tb/publications/tb-diabetes-framework/en/ accessed: 5 January 2018. - PubMed
    1. Pai M.; Behr M. A.; Dowdy D.; Dheda K.; Divangahi M.; Boehme C. C.; Ginsberg A.; Swaminathan S.; Spigelman M.; Getahun H.; et al. Tuberculosis. Nat. Rev. Dis. Primers 2016, 2, 16076.10.1038/nrdp.2016.76. - DOI - PubMed
    1. WHO “Multidrug-Resistant Tuberculosis (MDR-TB) 2016 Update”, World Health Organization, 2016 ; http://www.who.int/tb/challenges/mdr/mdr_tb_factsheet.pdf accessed: 29 September 2017.

Publication types

MeSH terms

Substances